高人群免疫背景下持续COVID-19疫苗接种的成本效果:国际经济学证据结构化综述
该结构化综述检索2025年12月前的MEDLINE、Embase和EconLit及灰色文献,纳入2023年起发表的21项COVID-19疫苗接种经济学评价,按人群分组汇总成本效果。结果显示,老年人(≥60-65岁)年度接种在所有18项贡献研究中均具经济优势,而有基础疾病者结果不一,健康工作年龄成人和儿童在标准阈值下多不具经济性。
要点
- 老年人(≥60-65岁)年度COVID-19疫苗接种在12国18项研究中均具经济优势。
- 有基础疾病者成本效果因年龄、具体疾病和疫苗价格而异,结果不一。
- 健康工作年龄成人和儿童接种在标准成本效果阈值下多不具经济性。
核心结论
- 经济学证据支持对COVID-19疫苗接种采取风险分层策略,老年人及有合并症者经济价值最强。
- 成本效果是动态的,对疾病负担、疫苗价格和人群特征敏感,应随流行病学条件变化定期重新评估。
研究设计与样本
- 结构化文献检索于2025年12月覆盖MEDLINE、Embase和EconLit,并补充国家免疫技术咨询组(NITAG)网站灰色文献。
- 从644篇筛选文献中纳入21项2023年起发表的经济学评价,比较年度接种与不额外接种,报告QALYs或DALYs的成本效果,按人群分组汇总。
主要发现
- 老年人(≥60-65岁)年度接种在所有18项贡献研究中均具经济优势,覆盖12个国家并使用多种分析方式。
- 有基础疾病或合并症者结果更可变,成本效果取决于年龄、具体疾病和疫苗价格。
- 健康工作年龄成人(4项研究中3项)和儿童(3项研究中2项)接种在标准成本效果阈值下通常不具经济性。
- 医务人员证据有限,2023年起未识别到妊娠人群的经济学评价。
- 证据基础地理上集中于高收入国家,约半数纳入研究报告产业资助;美国系列经济学评价显示成本效果随疾病负担下降而逐步降低。
临床怎么用
- 优先为老年人(≥60-65岁)及有合并症者安排持续COVID-19疫苗接种,以获取最强经济价值。
- 对健康工作年龄成人和儿童常规接种需谨慎评估,因标准阈值下多不具经济性。
局限性
- 证据地理上集中于高收入国家,约半数纳入研究报告产业资助。
- 医务人员证据有限,妊娠人群缺乏2023年起的经济学评价。
- 成本效果随疾病负担、疫苗价格和人群特征动态变化,需定期重新评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the context of ongoing SARS-CoV-2 circulation and high population immunity, jurisdictions face decisions about which population groups should receive ongoing annual vaccination. Economic evaluations are increasingly central to these deliberations but the growing body of global cost-effectiveness evidence has not been synthesized. OBJECTIVE: To summarize cost-effectiveness evidence for COVID-19 vaccination from 2023 onwards, organized by population groups of policy relevance. METHODS: We conducted a structured literature search in December 2025 across MEDLINE, Embase, and EconLit, supplemented by grey literature searches of National Immunization Technical Advisory Group (NITAG) websites. From 644 screened references, 21 studies met inclusion criteria: economic evaluations of COVID-19 vaccination from 2023 onwards reporting cost-effectiveness of annual vaccination compared to no additional vaccination in quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). Results were synthesized by population group. RESULTS: Annual COVID-19 vaccination was economically favourable for older adults (≥60-65 years) across all 18 contributing studies spanning 12 countries and using diverse analytic approaches. For individuals with underlying conditions or comorbidities, results were more variable, with cost-effectiveness depending on age, specific conditions, and vaccine price. Vaccination of healthy working-age adults (3 of 4 studies) and children (2 of 3 studies) was generally unfavourable at standard cost-effectiveness thresholds. Limited evidence was identified for healthcare workers and no economic evaluations from 2023 onwards were identified for pregnancy. The evidence base was geographically concentrated in high-income countries, with approximately half of included studies reporting industry funding. Sequential US economic evaluations demonstrated progressive declines in cost-effectiveness as disease burden decreased over time. CONCLUSIONS: The economic evidence supports a risk-stratified approach to COVID-19 vaccination, with the strongest economic value observed for older adults and individuals with comorbidities. Cost-effectiveness is dynamic, sensitive to disease burden, vaccine price, and population characteristics, and should be reassessed regularly as epidemiological conditions evolve.
引用
- Tuite AR, Forbes N, Salvadori MI, et al. Cost-effectiveness of ongoing COVID-19 vaccination in the context of high population immunity: A structured review of international economic evidence. Vaccine. 2026. PMID: 42085748. doi:10.1016/j.vaccine.2026.128660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。